Charles Reay Mackay joins Pfizer
This article was originally published in Scrip
Pfizer has named Charles Reay Mackay chief scientific officer for its inflammation and immunology research unit. Professor Mackay will report directly to José-Carlos Gutiérrez-Ramos, group vice-president of BioTherapeutics R&D, and will be based in Pfizer's R&D hub in Cambridge, Massachusetts. Professor Mackay will join Pfizer from Monash University in Australia, where he is a research fellow, and the Charles Perkins Center within the Faculty of Medicine at Sydney University, where he was chair of diabetes. Inflammation and immunology is one of Pfizer's key therapeutic areas.